KemPharm, Inc. to Present at Upcoming Investor Conferences

CORALVILLE, Iowa, Feb. 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the RBC Capital Markets 2016 Healthcare Conference being held in New York, NY, February 23-24, 2016. Dr. Mickle will also present at the Cowen & Co. 36th Annual Health Care Conference 2016 being held in Boston, MA, March 7-9, 2016.

Details of KemPharm's presentations are as follows:

RBC Capital Markets 2016 Healthcare Conference Date:        Tuesday, February 23, 2016Time:        3:35 PM (ET)Location:  The New York Palace Hotel in New York, NY

Cowen & Co. 36th Annual Health Care Conference 2016 Date:        Monday, March 7, 2016Time:        4:40 PM (ET)Location:  The Boston Marriott Copley Place in Boston, MA

The presentations will be webcast and available on the Investor Relations section of KemPharm's website at http://investors.kempharm.com/.

About KemPharm

KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology.  KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders. 

Investor Contacts:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
[email protected]
[email protected]

Media Contact:
Jim Heins
Cooney Waters Unlimited
212-886-2221
[email protected]

You May Also Be Interested In

• Watershed Roofing Inc. Expands Roofing and Exterior Services Across British Columbia
• The Games DEA Attorneys Play: What Marijuana Rescheduling Closing Brief Didn't Tell Judge Julius
• Latest Crypto News: Bitcoin Rips Past $77K, Cardano Turns Bullish – Is Apeing Whitelist the Next Move for Traders?